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Summary For neuro-oncologists, much was accom-
plished in the last decade, including the establishment
of the first standard of care (SOC) in this field of oncol-
ogy. New treatment options boosted research in the
whole field of neuro-oncology, as well clinical trials,
translational and basic research. Accumulated data
on molecular–genetic subgroups with distinct clinical
outcomes in disease entities led to the establishment
of new biomarkers and to the collaborative formula-
tion of a new WHO classification of central nervous
system tumors.
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For neuro-oncologists, the last decade was a labori-
ous period of time, following the establishment of the
first standard of care (SOC) in the field of oncology,
e. g., the SOC for the first line treatment of adult pa-
tients with newly diagnosed glioblastoma multiforme
(GBM) in 2005 [1]. This SOC consisting of maximal
feasible safe tumor resection, followed by 6 weeks of
radiochemotherapy with temozolomide and adjuvant
temozolomide became the treatment paradigm in the
world and this resulted in prolonging the survival of
GBM patients for the first time after decades of frus-
trating stagnancy [2, 3]. This boosted research in the
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whole field of neuro-oncology, as well clinical trials as
translational and basic research.
Accumulated data on molecular–genetic subgroups
with distinct clinical outcomes in disease entities led
to the establishment of new biomarkers and to the
collaborative formulation of a new WHO classification
of central nervous system tumors CNS4+ which was
published in June 2016 [4–6]. This new classification
of CNS tumors integrating classical histological clas-
sification, grading, and immunohistochemical and
molecular–genetic data is a major milestone in the
development of neuro-oncology and will allow a bet-
ter characterization of tumors as better assignment
of treatments, will most probably allow more rapidly
informative trial results on better defined, more ho-
mogenous patient populations to be obtained. This
new classification will undoubtedly speed up scien-
tific progress in all domains of neuro-oncology in the
following years.
Glioblastoma multiforme
The prolongation of survival achieved by adding
temozolomide to radiotherapy and performing adju-
vant chemotherapy with temozolomide is not equally
distributed among all patients with GBM, but re-
stricted to those in whose tumors the promoter of
the DNA repair enzyme methylguanine-methyltrans-
ferase (MGMT) is methylated, allowing the efficacy of
alkylating chemotherapy [7, 8]. This is also true for
all other gliomas or other tumors where MGMT pro-
moter methylation allows alkylating chemotherapies
to be effective.
In the following years, a number of trials have
been conducted in order to improve the actual SOC
in GBM, but no further breakthrough with drug ther-
apy has yet been achieved. Neither intensifying the
dose, nor prolonging the exposure to temozolomide
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[9] nor adding the integrin-inhibitor cilengitide [10,
11], nor the anti-VEGF antibody bevacizumab [12,
13] was able to prolong the survival of patients as
compared to control patients treated according to the
current SOC. Most remarkably, advances in surgery
and radiotherapy lead to a prolongation of the median
overall survival to 18–20 months in the most recent
trials. However, there was a positive study using an
electrical device for maintenance of remission possi-
bly leading to a survival gain of a further 3 months;
Novocure TTF [14] delivers alternating electrical fields
to the brain, but the mode of action of this therapy
remains unclear, as well as the burden to quality of life
and the cost effectiveness of this device. Currently,
several trials are investigating the addition of im-
mune therapy as dendritic cell vaccines and immune
checkpoint inhibitors in glioblastoma patients.
For elderly patients with glioblastoma, Lawrence
et al. analyzed the outcomes of treatment in the
Survival, Epidemiology and End Results Database for
patients diagnosed with GBM from 2001–2007 in the
US and showed that on a population-based level the
survival of the elderly with GBM still stagnated at
a median duration of 4 months [2]. During the last
decade, a number of trials has quasi systematically
cleared how to treat glioblastoma in the elderly; how-
ever, none of these trials included a formal geriatric
assessment—which would greatly help to allocate
treatment to patients. Keime Guilbert et al. demon-
strated a significant prolongation of overall survival
in patients treated with radiotherapy plus support-
ive care, versus supportive care alone (29.1 weeks
for RT vs 16.9 weeks, hazard ratio [HR] 0.47; P =
0.002) [15]. Roa et al. had already shown in 2004
that hypofractionated radiotherapy, e. g., 40Gy/15
fractions over 3 weeks, achieved similar survival data
to the standard radiation course with 60Gy/30 frac-
tions [16]. Furthermore, the NOA-08 trial and the
Nordic Glioma trial both explored radiation therapy
versus chemotherapy with temozolomide (TMZ) in
two different elderly patients cohorts, both show-
ing that alkylating chemotherapy is beneficial only
in patients with GBM with methylated MGMT pro-
moter, whereas radiotherapy also prolongs survival
in patients whose tumors are unmethylated [17–19].
Finally, Perry presented at ASCO 2016 a collabora-
tive trial showing that combining hypofractionated
radiotherapy (40Gy/3 weeks)with TMZ, followed by
adjuvant TMZ was the most effective treatment also
in elderly GBM patients [20].
Based on preclinical data showing expression of im-
mune-related molecules and infiltration by immune
cells in brain tumors, as well as promising results
from animal studies, clinical trials with immunomod-
ulatory substances including vaccines and immune
check-point inhibitors are ongoing and outcomes will
be reported in the near future [21].
Anaplastic gliomas WHO III
As diagnostic criteria for WHO III gliomas have
changed substantially in the past years and as the
interobserver variation in those diagnoses is well-
known to be huge, it is difficult to interpret results
from previous trials with recent patients.
For patients with WHO grade III gliomas, two piv-
otal trials led by the EORTC are currently being con-
ducted, exploring timing and sequence of the cur-
rently available treatments:
● CODEL trial for patients withWHOgrade III gliomas
with codeletion of 1p/19q; currently again recruit-
ing, comparing radiotherapy alone to radiother-
apy followed with procarbazine, CCNU, vincristine
(PCV) and to radiotherapy + concomitant and ad-
juvant temozolomide. Results of this trial will be
available only in a few years.
● TheCATNON trial addressing treatment for anaplas-
tic gliomas without 1p/19q codeletion, a four-arm
trial with a 2:2 design, exploring radiotherapy (RT)
alone, compared to RT ± concomitant and ± adju-
vant temozolomide has finished recruitment of 748
patients. The first planned interim analysis at the
end of 2015 after a median follow-up of 27 months
showed a HR reduction for overall survival (OS) of
0.645 (95% confidence interval [CI] 0.450–0.926; p =
0.0014) using adjuvant temozolomide. Whether also
concomitant chemotherapy is beneficial in these
patients will be known in 2021.
Diffuse gliomas WHO II
For patients with diffuse gliomas, the management
showed the greatest changes with moving away from
the common practice consisting in prolonging ob-
servation without intervention as long as possible
to active treatment using all modalities. Resecting
the gliomas as much as possible without causing
a neurological deficit precludes transformation into
a higher grade glioma. Furthermore, two studies
started more than 10 years ago both showed benefit
from radiotherapy as well as from chemotherapy in
patients with symptomatic low grade gliomas (LGGs).
Buckner et al. reported the results of the RTOG 9802
trial showing a survival benefit with PCV added after
radiotherapy, resulting in a significant survival gain of
patients treated with subsequent PCV, e. g., 7.8 years
vs. 13.3 years, respectively (HR 0.59, p < 0.003) [22,
23]. In the EORTC trial 22033, patients with LGG were
first registered and 477 patients were randomized to
either radiotherapy or dose dense chemotherapy with
temozolomide at a later time point, when radiologic
tumor progression or progression of symptoms oc-
curred [24]. After a median follow-up of 48 months,
patients with IDH1 mutation and 1p/19q codeletion
had the longest period of progression-free survival
(PFS) of 62 months (95% CI 41–not reached), fol-
lowed by the patients showing IDH mutation only
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(48 months, range 41–55months), whereas patients
with IDH wild-type had the shortest PFS of 20 months
(range 12–26months). IDH mutated, non-codel pa-
tients experienced a longer period of PFS with radio-
therapy than with chemotherapy (55.4 vs 36 months,
respectively, p = 0.013). Quality of life and cogni-
tive performance were examined prospectively in this
trial and showed so far no difference in effect of temo-
zolomide chemotherapy or radiotherapy neither on
health-related quality of life nor on global cognitive
functioning [25].
Meningiomas
Although approximately 80% of meningiomas can
be cured by surgical resection, about 20% of cases
progress or recur due to unfavorable location preclud-
ing complete resection or histological or molecular
features associated with tumor growth and treatment
resistance. Approximately half of meningioma cases
carry NF2 aberrations and recent studies have identi-
fied other recurring molecular alterations such as AKT
mutations, SMO mutations, PI3K mutations, TERT
promoter mutations, and gene promoter methylation
profiles that show strong correlations with tumor loca-
tion, tumor histology, and clinical course. These find-
ings will most likely translate into updated classifica-
tion schemes for meningioma in the near future that
will integrate morphological and molecular features,
similar to recent advancement in the classification of
other brain tumors. Ongoing clinical trials are evalu-
ating not only the role of adjuvant radiotherapy after
resection of completely resected newly diagnosed
grade II meningiomas (ROAM trial, [26]), but are also
evaluating cytotoxic chemotherapy with trabectedin
for recurrent grade II/III meningiomas (EORTC-13020
trial, NCT02234050) and targeted therapy according
to molecular profile in recurrent meningioma of all
grades (NCT02523014). Overall, meningioma research
has evolved into a highly active and interesting field of
research with rapid advancements in molecular un-
derstanding and an active clinical trial portfolio that
will hopefully lead to improved treatment modalities
within the next few years.
Brain metastases
Brain metastases are the most common intracranial
malignant tumors in adults and affect up to 30% of
cancer patients. The incidence of brain metastases
seems to be increasing over time, probably due to
longer survival of cancer patients with new treatment
opportunities and improved diagnostic methods. The
main strategies of brain metastasis treatment have
long been radiotherapy, surgery, and palliative care.
However, in recent years molecular treatments with
activity in extracerebral tumor types have been shown
to also be useful in some patients with brain metas-
tases. Examples include EGFR and ALK inhibitors
in non-small cell lung cancer, BRAF inhibitors in
melanoma, HER2-targeting agents in breast cancer,
immune check-point inhibitors of CTLA4 or PD1 in
melanoma or non-small cell lung cancer and be-
vacizumab in patients with radionecrosis of corti-
costeroid-refractory brain edema [27]. These novel
treatment options are increasingly being considered
in brain metastasis patients and may help to signifi-
cantly improve the prospects of patients affected by
this dreadful manifestation of cancer. Hopefully, more
clinical trials will emerge that help to define treat-
ment algorithms for evidence-based decision-making
regarding optimal combinations and sequence of
treatments for brain metastasis patients.
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